Evidence map›Paper›PMID 37368170›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2023

Metachronous primary gastric cancer after endoscopic resection in patients with esophageal squamous cell carcinoma.

Motohiro Hirao, Chikatoshi Katada, Tetsuji Yokoyama, Tomonori Yano, Haruhisa Suzuki, Yasuaki Furue, Keiko Yamamoto, Hisashi Doyama, Tomoyuki Koike, Masashi Tamaoki and 11 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 1 country.

Motohiro HiraoDepartment of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Chikatoshi KatadaDepartment of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawaharacho Syhogoin Sakyo, Kyoto, 606-8507, Japan. ckatada@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0002-2713-4661
Tetsuji YokoyamaDepartment of Health and Promotion, National Institute of Public Health, Wako, Japan.
Tomonori YanoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Haruhisa SuzukiEndoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Yasuaki FurueDepartment of Gasroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
Keiko YamamotoDivision of Endoscopy, Hokkaido University Hospital, Sapporo, Japan.
Hisashi DoyamaDepartment of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
Tomoyuki KoikeDivision of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masashi TamaokiDepartment of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawaharacho Syhogoin Sakyo, Kyoto, 606-8507, Japan.
Noboru KawataDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Yoshiro KawaharaDepartment of Practical Gastrointestinal Endoscopy, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Atsushi KatagiriDepartment of Medicine, Division of Gastroenterology, Showa University Hospital, Tokyo, Japan.
Takashi OgataDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Takenori YamanouchiDepartment of Gastroenterology, Kumamoto Regional Medical Center, Kumamoto, Japan.
Hirofumi KiyokawaDivision of Gastroenterology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Hirofumi KawakuboDepartment of Surgery, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan.
Maki KonnoDepartment of Gastroenterology, Tochigi Cancer Center, Utsunomiya, Japan.
Hideki IshikawaDepartment of Molecular-Targeting Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Akira YokoyamaClinical Research Unit, National Hospital Organization Kurihama Medical and Addiction Center, Yokosuka, Japan.
Manabu MutoDepartment of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawaharacho Syhogoin Sakyo, Kyoto, 606-8507, Japan.
Kyoto University · JPNational Cancer Center Hospital East · JPHokkaido University Hospital · JPIshikawa Prefectural Central Hospital · JPKanagawa Prefectural Hospital Organization · JPKawasaki Hospital · JPKitasato University · JPKumamoto Medical Center · JPKurihama Medical and Addiction Center · JPKyoto Prefectural University of Medicine · JPNational Institute of Public Health · JPOkayama University · JPOsaka National Hospital · JPShizuoka Cancer Center · JPShowa University Hospital · JPSt. Marianna University School of Medicine · JPTochigi Cancer Center · JPTohoku University · JP

Funding

National Cancer Center Research and Development Fund 36
6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the risk factors for developing metachronous primary Gastric Cancer (GC) after Endoscopic Resection (ER) for esophageal Squamous Cell Carcinoma (SCC).

methodsWe studied 283 patients with esophageal SCC who underwent ER. The study outcomes were as follows: (1) incidence of metachronous primary GC after ER; and (2) predictors for the development of metachronous primary GC after ER by the Cox proportional hazards model.

resultsThe median follow-up was 43.1 months (1.81-79.1), and the 3-year cumulative incidence of metachronous primary GC was 6.5% (95%CI: 4.1-10.4). The incidence of metachronous primary GC during the follow-up period was 2.31 per 100 person-years. The frequencies of severe gastric atrophy and macrocytosis at the timing of ER were significantly higher in patients with than without metachronous primary GC (91.7% vs. 73.2%, p = 0.0422, 20.8% vs. 5.2%, p = 0.0046, respectively). Severe gastric atrophy was associated with the development of metachronous primary GC (sex-and-age adjusted hazard ratio (HR) [95%CI] = 4.12 [0.95-27.78], p = 0.0093). Macrocytosis was associated with the development of metachronous primary GC (sex-and-age adjusted HR = 4.76 [1.75-13.0], p = 0.0012) and found to be an independent predictor for metachronous primary GC by multivariate Cox proportional hazards analysis (HR [95%CI] = 4.35 [1.60-11.84], p = 0.004).

conclusionsSevere gastric atrophy and macrocytosis should be noted in the development of metachronous primary GC after ER for esophageal SCC. In particular, macrocytosis at the timing of ER was considered an important predictor. CLINICAL TRIALS REGISTRY NUMBER: UMIN000001676.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaGastritis, AtrophicNeoplasms, Second PrimaryStomach NeoplasmsAtrophyHumansRetrospective StudiesRisk FactorsEndoscopic resectionEsophageal cancerGastric cancerMacrocytosisMetachronous cancer

Identifiers

PMID37368170
OpenAlexW4382182687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.